Evidence map›Paper›PMID 41770477›Full record

ArticleDiscover oncology2026

Single cell and multi-omics analysis reveal senescence-related molecular subtypes and a prognostic signature in clear cell renal cell carcinoma.

Jiawei Wang, Weiyu Kong, Wenchuan Shao, Zijie Yu, Heqian Liu, Zehong Gao, Yingqing Liu, Yuting Zhao, Lingsong Tao, Mingcong Zhang and 1 more

Abstract read
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiawei Wang *Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Weiyu Kong *Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Wenchuan Shao *Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Zijie Yu *Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Heqian LiuDepartment of Urology, The Second People's Hospital of Wuhu, Wuhu, Anhui, China.
Zehong GaoDepartment of Urology, The Second People's Hospital of Wuhu, Wuhu, Anhui, China.
Yingqing LiuDepartment of Urology, The Second People's Hospital of Wuhu, Wuhu, Anhui, China.
Yuting ZhaoDivision of oncology, Department of Medicine, McDonnell Genome Institute, Washington University School of Medicine, Washington University in St. Louis, St. Louis, MO, 63130, USA.
Lingsong TaoDepartment of Urology, The Second People's Hospital of Wuhu, Wuhu, Anhui, China. taolingsong@sina.com.
Mingcong ZhangDepartment of Urology, Affiliated Lianyungang Clinical College of Nantong University, Lianyungang, 222006, Jiangsu, China. zhangmingcong@lygey.com.
Chaozhao LiangDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. liang_chaozhao@ahmu.edu.cn.

Funding

Anhui Provincial Health Research AHWJ20226100
6 · The paper itself

Abstract

backgroundClear cell renal cell carcinoma (ccRCC) is the most prevalent subtype of renal cancer and represents high heterogeneity and poor prognosis. Current evidence highlights that the senescence program, particularly through SASP, can simultaneously impose tumor-suppressive barriers and, under specific conditions, support malignant progression. Nevertheless, the comprehensive characterization and clinical significance of cellular senescence in ccRCC have yet to be fully elucidated.

methodsWe integrated single-cell and bulk transcriptomic data to characterize senescence-associated features in ccRCC. Single-cell RNA sequencing (scRNA-seq) data from normal, peritumoral, and tumor tissues (GSE222703 and GSE210042) were used to assess SASP signatures across cell types. Differentially expressed senescence-associated genes (SAGs) were identified from TCGA-KIRC and used for consensus clustering. A risk score model was constructed using Random Survival Forest (RSF) based on key SAGs and validated across three independent cohorts [TCGA-KIRC (n = 537), E-MTAB-1980 (n = 101), and CPTAC-ccRCC (n = 105)]. Immune cell infiltration, clinical associations, and prognostic utility were further evaluated. A nomogram was developed and tested for survival prediction.

resultsSenescence signatures were enriched in epithelial tumor cells, especially in ccRCC tissues compared to normal and peritumoral tissues. Two distinct molecular subtypes (C1 and C2) were defined by SAG expression, with C1 exhibiting stronger senescence activity and better survival outcomes. The RSF-based risk score showed robust performance across all cohorts and was independently associated with survival. High-risk patients displayed lower immune activation, reduced antigen presentation, and a more immunosuppressive microenvironment. A survival nomogram integrating the risk score with clinical parameters achieved high predictive accuracy. Among all SAGs, ALDH18A1 was identified as a key prognostic gene and was significantly upregulated in ccRCC. In addition, single-cell sequencing analysis revealed substantial interactions between ALDH18A1

conclusionsIn this study, we uncovered the diverse patterns of cellular senescence within ccRCC and developed a senescence-derived risk score that demonstrated strong prognostic value. Moreover, ALDH18A1 was identified as a promising biomarker for prognosis and a potential therapeutic target in ccRCC.

Indexed as

ALDH18A1ccRCCPrognosisSenescenceSubtypes

Identifiers

PMID41770477
PMCPMC13057107

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.